Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
- PMID: 25555261
- PMCID: PMC4728189
- DOI: 10.1016/j.gde.2014.12.001
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
Abstract
Intratumour heterogeneity complicates biomarker discovery and treatment personalization, and pervasive cancer evolution is a key mechanism leading to therapy failure and patient death. Thus, understanding subclonal heterogeneity architectures and cancer evolution processes is critical for the development of effective therapeutic approaches which can control or thwart cancer evolutionary plasticity. Current insights into heterogeneity are mainly limited to the macroheterogeneity level, established by cancer subclones that have undergone significant clonal expansion. Novel single cell sequencing and blood-based subclonal tracking technologies are enabling detailed insights into microheterogeneity and the dynamics of clonal evolution. We assess how this starts to delineate the rules governing cancer evolution and novel angles for more effective therapeutic intervention.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures
References
-
- Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501:338–345. - PubMed
-
- Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle. 2009;8:505–506. - PubMed
-
- Gerlinger M., McGranahan N., Dewhurst S.M., Burrell R.A., Tomlinson I., Swanton C. Cancer: evolution within a lifetime. Annu Rev Genet. 2014;48:215–236. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
